iBio plans first-in-human trial of obesity drug candidate IBIO-610 in H1 2027

Bitget2026/10/13 11:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

iBio highlighted preclinical data on IBIO-610 from an obese non-human primate study, with results already presented at EASD on Oct. 1, 2026.
In combination with semaglutide, IBIO-610 shifted weight loss toward fat, suggesting improved muscle preservation versus semaglutide alone.
iBio expects to start first-in-human trials of IBIO-610 in the first half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. iBio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610130700PRIMZONEFULLFEED9844181) on October 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

iBio plans first-in-human trial of obesity drug candidate IBIO-610 in H1 2027

You may also like

Crypto prices